Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
BLFS

BLFS - BioLife Solutions Inc Stock Price, Fair Value and News

19.96USD-0.29 (-1.43%)Market Closed

Market Summary

BLFS
USD19.96-0.29
Market Closed
-1.43%

BLFS Alerts

  • 1 major insider sales recently.
  • Big fall in Revenue (Y/Y)
  • Losses in recent quarter

BLFS Stock Price

View Fullscreen

BLFS RSI Chart

BLFS Valuation

Market Cap

918.8M

Price/Earnings (Trailing)

-14.6

Price/Sales (Trailing)

6.69

EV/EBITDA

-16.73

Price/Free Cashflow

-44.51

BLFS Price/Sales (Trailing)

BLFS Profitability

EBT Margin

-45.69%

Return on Equity

-18.88%

Return on Assets

-15.67%

Free Cashflow Yield

-2.25%

BLFS Fundamentals

BLFS Revenue

Revenue (TTM)

137.3M

Rev. Growth (Yr)

-15.85%

Rev. Growth (Qtr)

-3.07%

BLFS Earnings

Earnings (TTM)

-62.9M

Earnings Growth (Yr)

25.47%

Earnings Growth (Qtr)

23.62%

Breaking Down BLFS Revenue

Last 7 days

-6.8%

Last 30 days

-9.1%

Last 90 days

11.5%

Trailing 12 Months

-15.5%

How does BLFS drawdown profile look like?

BLFS Financial Health

Current Ratio

2.89

Debt/Equity

0.05

Debt/Cashflow

-0.91

BLFS Investor Care

Shares Dilution (1Y)

5.92%

Diluted EPS (TTM)

-1.42

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024137.3M000
2023163.2M162.2M154.8M143.3M
2022138.5M147.9M154.8M161.8M
202152.8M74.1M96.6M119.2M
202033.8M37.0M41.7M48.1M
201921.7M23.2M24.5M27.4M
201812.5M15.1M17.4M19.7M
20178.7M9.3M10.1M11.0M
20166.8M7.3M7.8M8.2M
20155.6M5.9M6.3M6.4M
20149.6M8.5M7.6M6.2M
20135.4M6.7M7.2M8.2M
20123.0M3.5M4.4M5.7M
20112.3M2.4M2.6M2.8M
20100002.1M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of BioLife Solutions Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 14, 2024
berard todd
sold
-201,800
20.18
-10,000
chief marketing officer
May 29, 2024
berard todd
sold
-7,514
21.78
-345
chief marketing officer
May 29, 2024
mathew aby j.
sold
-11,260
21.78
-517
evp & chief scientific officer
May 29, 2024
wichterman troy
sold
-12,501
21.78
-574
chief financial officer
May 29, 2024
aebersold sarah
sold
-7,514
21.78
-345
chief human resources officer
May 29, 2024
foster karen a.
sold
-8,886
21.78
-408
chief quality and operations
May 17, 2024
wichterman troy
sold
-2,550
22.18
-115
chief financial officer
May 17, 2024
foster karen a.
sold
-1,885
22.18
-85.00
chief quality and operations
May 17, 2024
berard todd
sold
-1,619
22.18
-73.00
chief marketing officer
May 17, 2024
mathew aby j.
sold
-2,173
22.18
-98.00
evp & chief scientific officer

1–10 of 50

Which funds bought or sold BLFS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
22,000
184,000
-%
May 16, 2024
Beacon Capital Management, LLC
new
-
872
872
-%
May 16, 2024
Pineridge Advisors LLC
reduced
-94.04
-6,603
482
-%
May 16, 2024
COMERICA BANK
reduced
-1.12
35,888
314,677
-%
May 16, 2024
JANE STREET GROUP, LLC
new
-
351,022
351,022
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-1.99
70,834
667,225
-%
May 15, 2024
SHERBROOKE PARK ADVISERS LLC
new
-
266,155
266,155
0.05%
May 15, 2024
Curi RMB Capital, LLC
added
5.63
1,333,710
7,813,750
0.18%
May 15, 2024
BANK OF AMERICA CORP /DE/
added
59.75
4,157,590
9,205,720
-%
May 15, 2024
Casdin Capital, LLC
unchanged
-
20,026,500
161,518,000
12.01%

1–10 of 46

Are Funds Buying or Selling BLFS?

Are funds buying BLFS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BLFS
No. of Funds

Unveiling BioLife Solutions Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
5.71%
2,571,608
SC 13G/A
Feb 02, 2024
goldman sachs group inc
5.5%
2,476,242
SC 13G
Jan 24, 2024
integrated core strategies (us) llc
5.3%
2,404,862
SC 13G/A
Jan 23, 2024
blackrock inc.
12.3%
5,424,116
SC 13G/A
Oct 24, 2023
casdin capital, llc
19.5%
8,707,165
SC 13D/A
Sep 26, 2023
integrated core strategies (us) llc
5.5%
2,406,913
SC 13G
Feb 09, 2023
vanguard group inc
5.77%
2,466,931
SC 13G/A
Jan 26, 2023
blackrock inc.
12.8%
5,477,126
SC 13G/A
Jan 20, 2023
blackrock inc.
12.8%
5,477,126
SC 13G/A
Jan 11, 2023
millennium management llc
1.6%
670,202
SC 13G/A

Recent SEC filings of BioLife Solutions Inc

View All Filings
Date Filed Form Type Document
Jun 18, 2024
4
Insider Trading
Jun 05, 2024
DEF 14A
DEF 14A
May 31, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 21, 2024
4
Insider Trading
May 21, 2024
4
Insider Trading
May 21, 2024
4
Insider Trading

Peers (Alternatives to BioLife Solutions Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
181.0B
40.3B
-0.10% -2.08%
32.14
4.49
-2.84% -3.00%
67.5B
19.7B
-1.04% -9.58%
50.67
3.43
4.82% -17.56%
18.2B
3.9B
-10.79% -26.67%
39.44
4.66
5.72% 46.72%
17.2B
14.9B
-4.26% -25.60%
6.49
1.15
2.98% 207.68%
MID-CAP
9.7B
3.5B
-0.60% 25.29%
31.07
2.74
6.16% 35.06%
8.7B
12.4B
-8.47% -12.48%
22.53
0.7
-0.93% -18.83%
8.2B
2.6B
-1.69% -23.28%
-25.56
3.16
-6.25% -68.58%
5.3B
3.9B
-9.26% -35.41%
-55.79
1.35
0.23% 90.80%
3.4B
387.1M
-0.06% 30.91%
-216.17
8.9
30.82% 65.57%
2.2B
6.6B
-1.48% -10.95%
12.01
0.34
1.50% -10.29%
SMALL-CAP
1.5B
3.2B
12.63% 11.29%
-2.15
0.46
7.94% -1695.32%
384.5M
169.3M
2.09% -2.41%
-5
2.27
7.49% -244.90%
226.3M
324.0M
-6.46% -49.01%
-1.18
0.7
-3.19% -337.41%
47.1M
50.5M
-15.62% -80.60%
-2.07
0.93
14.25% -10.06%
1.8M
3.7M
70.00% -81.62%
-0.15
0.48
5.77% 8.23%

BioLife Solutions Inc News

Latest updates
MarketBeat21 hours ago
Seeking Alpha09 May 202407:00 am

BioLife Solutions Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-3.1%31,727,00032,732,50033,328,00039,508,00037,703,00044,259,00040,747,00040,533,00036,220,00037,305,00033,800,00031,204,00016,847,00014,726,00011,279,0009,920,00012,162,0008,296,0006,604,0006,701,0005,770,000
Gross Profit-------------------4,520,0004,743,0004,123,000
Costs and Expenses-8.8%41,855,00045,888,50062,111,00054,788,00051,308,00093,530,00052,487,000117,096,00044,187,00055,770,00044,959,00035,759,00017,828,00020,135,00012,525,0009,876,00011,792,0009,057,0007,376,0005,954,0005,204,000
Operating Expenses-------------------7,376,0005,954,0005,204,000
  S&GA Expenses11.7%5,070,0004,538,0007,256,0006,318,0006,471,0005,977,5005,278,0005,415,0004,891,0004,778,0004,065,0003,142,0002,021,0001,883,0001,588,0001,366,0001,576,0001,669,0001,250,000945,000837,000
  R&D Expenses-19.7%3,534,0004,400,5005,402,0004,840,0004,152,0004,164,0003,425,0003,428,0003,781,0003,570,5003,219,0003,045,0001,987,0001,855,0001,725,0001,477,0001,663,0001,086,0001,032,000691,000359,000
EBITDA Margin1.3%-0.39-0.40-0.60-0.46-0.87-0.85-0.69-0.68-0.22-0.20-0.14-0.14-0.42--------
Interest Expenses-16.5%445,000533,000459,000438,000497,000356,000109,00030,00091,000452,000----4,0003,000-1,000-5,0001,0001,0003,000
Income Taxes454.1%131,000-37,000115,0005,00092,000-85,000-599,000-3,739,000-599,000-2,578,000-4,988,000-12,552,000--3,264,000----1,541,000---
Earnings Before Taxes24.8%-10,090,000-13,425,000-29,017,000-10,194,000-13,622,000-49,274,000-10,916,000-76,617,000-8,020,000-18,323,000-4,909,000-4,676,000-1,118,000-6,076,000-1,133,000-16,380,00022,308,0001,442,00010,269,0004,252,000-19,161,000
EBT Margin1.2%-0.46-0.46-0.66-0.52-0.92-0.90-0.74-0.73-0.26-0.24-0.17-0.18-0.47--------
Net Income23.6%-10,221,000-13,382,000-29,132,000-10,199,000-13,714,000-49,189,000-10,317,000-72,878,000-7,421,000-15,745,00079,0007,876,000-1,118,000-2,812,000-1,133,000-16,380,00022,308,0002,983,00010,269,0004,252,000-19,161,000
Net Income Margin1.1%-0.46-0.46-0.66-0.51-0.89-0.86-0.69-0.65-0.11-0.070.040.04-0.41--------
Free Cashflow-510.2%-5,456,0001,330,000-5,875,000-8,327,000-6,007,0003,409,000-950,000-11,952,000-9,380,000-2,340,000-329,000-10,409,000100,000--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-2.7%40241341143344645048847154455455952124023519611495.0093.0084.0051.0048.00
  Current Assets-7.4%11212111712013313813611811912613112711711512846.0026.0024.0032.0029.0039.00
    Cash Equivalents-16.1%30.0035.0019.0021.0019.0019.0027.0024.0059.0070.0075.0076.0089.0090.0094.0030.006.006.0021.0020.0032.00
  Inventory-0.1%43.0043.0043.0039.0041.0035.0034.0033.0030.0028.0030.0026.0012.0012.0011.0011.0011.0011.006.005.004.00
  Net PPE-0.2%21.0021.0021.0026.0026.0024.0022.0019.0018.0018.0017.0016.0011.0010.005.005.005.006.002.001.001.00
  Goodwill0%22522522522522522522522522558.0022419658.0058.0025.0034.0034.0034.0028.0010.00-
Liabilities-9.1%68.0075.0079.0081.0088.0086.0083.0061.0068.0076.0070.0069.0031.0030.009.008.0027.0049.0049.0049.0052.00
  Current Liabilities-8.3%39.0042.0043.0040.0047.0045.0040.0036.0038.0043.0036.0031.0016.0016.008.007.0025.008.005.003.003.00
  Long Term Debt-14.4%16.0018.0021.0024.0024.0024.0024.006.006.006.006.005.00-1.00-------
    LT Debt, Current26.1%9.007.005.002.001.002.002.001.001.001.002.003.00-1.00-------
    LT Debt, Non Current-14.4%16.0018.0021.0024.0024.0024.0024.006.006.006.006.005.00-1.00-------
Shareholder's Equity-1.3%33333833235235836440541047647848945220920418710668.0043.0035.002.0044.00
  Retained Earnings-3.2%-325-314-299-270-260-246-197-187-114-107-90.55-90.63-98.50-97.38-95.26-94.12-77.74100-103-113-117
  Additional Paid-In Capital0.9%659653633623619612604598591585580543307303282200145143138115114
Accumulated Depreciation12.5%11.0010.00---------------3.002.002.002.00
Shares Outstanding1.2%46.0045.0044.0043.0043.0043.0042.0042.0042.0039.0037.0038.0033.00--------
Float----774---473---1,433---263---230-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-293.6%-4,4752,311-4,379-7,718-2,7127,8571,496-9,917-7,924-7742,083-7,7221,8202,257-5024,203687-1,0031,137-67.001,146
  Share Based Compensation-25.8%6,1838,3339,1176,8577,3637,6636,2995,9735,3995,0654,8672,5191,5052,1631,5601,1451,113864830818531
Cashflow From Investing-105.6%-2213,9571,6629,2922,926-14,894-15,883-25,070-2,270-2,542-2,007-4,216-4,427-22,057-975-456-1,227-14,021-292-12,549-156
Cashflow From Financing-109.7%-9529,841608704-562-62517,411-289-181-2,105-1,058-8311,2161,27280,58219,732492267743409177
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

BLFS Income Statement

2024-03-31
Unaudited Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Total product, rental, and service revenue$ 31,727$ 37,703
Costs and operating expenses:  
General and administrative12,93414,842
Sales and marketing5,0706,471
Research and development3,5344,152
Intangible asset amortization9141,459
Acquisition costs2370
Change in fair value of contingent consideration0720
Total operating expenses41,85551,308
Operating loss(10,128)(13,605)
Other income (expense):  
Interest expense, net(207)(411)
Other income245394
Total other income (expense), net38(17)
Loss before income tax expense(10,090)(13,622)
Income tax expense(131)(92)
Net loss(10,221)(13,714)
Net loss attributable to common shareholders:  
Basic(10,221)(13,714)
Diluted$ (10,221)$ (13,714)
Net loss per share attributable to common shareholders:  
Basic (in dollars per share)$ (0.22)$ (0.32)
Diluted (in dollars per share)$ (0.22)$ (0.32)
Weighted average shares used to compute loss per share attributable to common shareholders:  
Basic (in shares)45,432,42643,027,612
Diluted (in shares)45,432,42643,027,612
Product revenue  
Total product, rental, and service revenue$ 24,803$ 31,593
Costs and operating expenses:  
Cost of goods and services sold (exclusive of intangible assets amortization)14,38418,397
Service revenue  
Total product, rental, and service revenue5,0884,471
Costs and operating expenses:  
Cost of goods and services sold (exclusive of intangible assets amortization)3,5193,891
Rental revenue  
Total product, rental, and service revenue1,8361,639
Costs and operating expenses:  
Cost of goods and services sold (exclusive of intangible assets amortization)$ 1,263$ 1,376

BLFS Balance Sheet

2024-03-31
Unaudited Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 29,694$ 35,407
Restricted cash3131
Available-for-sale securities, current portion15,57916,288
Accounts receivable, trade, net of allowance for credit losses of $1,745 and $1,710 as of March 31, 2024 and December 31, 2023, respectively18,57418,657
Inventories43,41443,456
Prepaid expenses and other current assets4,4086,765
Total current assets111,700120,604
Assets held for rent, net6,9047,713
Property and equipment, net21,04221,077
Operating lease right-of-use assets, net10,77911,446
Financing lease right-of-use assets, net6594
Long-term deposits and other assets245273
Available-for-sale securities, long-term822548
Equity investments5,0695,069
Intangible assets, net20,23521,149
Goodwill224,741224,741
Total assets401,602412,714
Current liabilities:  
Accounts payable4,9846,940
Accrued expenses and other current liabilities8,86311,932
Sales taxes payable5,3955,442
Warranty liability7,8007,858
Lease liabilities, operating, current portion2,6452,797
Lease liabilities, financing, current portion352376
Debt, current portion8,6196,833
Total current liabilities38,65842,178
Lease liabilities, operating, long-term12,57913,205
Lease liabilities, financing, long-term1,0861,169
Debt, long-term15,68118,311
Deferred tax liabilities193188
Total liabilities68,19775,051
Commitments and contingencies (Note 12)
Shareholders’ equity:  
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of March 31, 2024 and December 31, 202300
Common stock, $0.001 par value; 150,000,000 shares authorized, 45,689,583 and 45,167,225 shares issued and outstanding, respectively, as of March 31, 2024 and December 31, 20234645
Additional paid-in capital659,063652,880
Accumulated other comprehensive loss, net of taxes(566)(345)
Accumulated deficit(325,138)(314,917)
Total shareholders’ equity333,405337,663
Total liabilities and shareholders’ equity$ 401,602$ 412,714
BLFS
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; ultra-low temperature mechanical freezers; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
 CEO
 WEBSITEbiolifesolutions.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES466

BioLife Solutions Inc Frequently Asked Questions


What is the ticker symbol for BioLife Solutions Inc? What does BLFS stand for in stocks?

BLFS is the stock ticker symbol of BioLife Solutions Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BioLife Solutions Inc (BLFS)?

As of Tue Jun 18 2024, market cap of BioLife Solutions Inc is 918.78 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BLFS stock?

You can check BLFS's fair value in chart for subscribers.

What is the fair value of BLFS stock?

You can check BLFS's fair value in chart for subscribers. The fair value of BioLife Solutions Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of BioLife Solutions Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BLFS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is BioLife Solutions Inc a good stock to buy?

The fair value guage provides a quick view whether BLFS is over valued or under valued. Whether BioLife Solutions Inc is cheap or expensive depends on the assumptions which impact BioLife Solutions Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BLFS.

What is BioLife Solutions Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Jun 18 2024, BLFS's PE ratio (Price to Earnings) is -14.6 and Price to Sales (PS) ratio is 6.69. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BLFS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on BioLife Solutions Inc's stock?

In the past 10 years, BioLife Solutions Inc has provided 0.259 (multiply by 100 for percentage) rate of return.